A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris
An Open, Multicenter, Phase III Extension Clinical Trial to Evaluate the Long-term Safety of ASC40 (Denifanstat) Tablets in Patients With Moderate to Severe Acne Vulgaris
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Xiang Leihong, Doctor
- Phone Number: 021-52888045
- Email: flora_xiang@vip.163.com
Study Contact Backup
- Name: Chen Qinyi, Doctor
- Phone Number: 021-52888045
- Email: qinyi_chen@aliyun.com
Study Locations
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200000
- Huashan Hospital Fudan University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants who have successfully completed a 12-week Phase III study of ASC40-303;
- Have fully understood this research and voluntarily signed the informed consent;
- The fertile male and female subjects of reproductive age agreed to use effective contraception from the time they signed the informed consent until 3 months after the final administration of the investigationa drug;
- Subjects are willing and able to complete the study, understand and comply with the study requirements, comply with the study requirements restrictions and related education, use the investigational drug as prescribed by the physician, and follow up according to the study schedule.
Exclusion Criteria:
- Discontinue participation in the ASC40-303 Phase III study for any reason;
- Are receiving/planning to receive any systemic acne medications, systemic retinoids, systemic corticosteroids, or any androgen/antiandrogen therapy (e.g., testosterone, spironolactone);
- Pregnant, nursing, or planning a pregnancy during the study period;
- Have major complications (including clinically significant abnormalities in clinical laboratory tests), mental disorders, or other factors deemed unsuitable for study participation by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ASC40 50mg
ASC40 50mg, up to 40 weeks of treatment.
|
ASC40 tablets orally once daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number and percentage of subjects with treatment emergent adverse events (TEAE)
Time Frame: From the first dose to 40 weeks of treatment.
|
The number and percentage of all subjects with treatment emergent adverse events (TEAE) from the first dose to 40 weeks of treatment.
|
From the first dose to 40 weeks of treatment.
|
|
Number and percentage of subjects with serious adverse event (SAE).
Time Frame: From the first dose to 40 weeks of treatment.
|
Number and percentage of subjects with serious adverse event (SAE) from the first dose to 40 weeks of treatment.
|
From the first dose to 40 weeks of treatment.
|
|
Number and percentage of subjects who discontinued due to adverse events.
Time Frame: From the first dose to 40 weeks of treatment.
|
Number and percentage of subjects who discontinued due to adverse events from the first dose to 40 weeks of treatment.
|
From the first dose to 40 weeks of treatment.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
At the end of the visit, the number of people whose IGA rating had decreased by at least 2 points from the baseline period of the study.
Time Frame: up to 40 weeks.
|
At the end of the visit, the number of subjects whose IGA rating had decreased by at least 2 points from the baseline period of the study.
|
up to 40 weeks.
|
|
At the end of the visit, the number of subjects with an IGA score of 3 or higher at baseline dropped to an IGA score of 0 or 1.
Time Frame: up to 40 weeks.
|
At the end of the visit, the number of subjects with an IGA score of 3 or higher at baseline dropped to an IGA score of 0 or 1 among all subjects.
|
up to 40 weeks.
|
|
Percentage change in total skin lesion count at the end of the visit compared to the baseline period of the study.
Time Frame: up to 40 weeks.
|
Percentage change in total skin lesion count at the end of the visit compared to the baseline period of the study.
|
up to 40 weeks.
|
|
Percentage change in total inflammatory skin lesion count at the end of the visit compared to the baseline period of the study.
Time Frame: up to 40 weeks.
|
Percentage change in total inflammatory skin lesion count for all subjects at the end of the visit compared to the baseline period of the study.
|
up to 40 weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ASC40-304
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.